Search Results for "Drug Interactions"
Search again or select article below to purchase. Single article price: $45. Order 3 or more at one time and receive a 10% discount.
Sort by relevance | Sort by date
Searched for Drug Interactions. Results 811 to 820 of 1090 total matches.
Linagliptin/Metformin (Jentadueto) for Type 2 Diabetes
The Medical Letter on Drugs and Therapeutics • May 14, 2012 (Issue 1390)
(no evidence of
risk in humans) for use during pregnancy.
DRUG INTERACTIONS — Linagliptin is a weak ...
Linagliptin (Tradjenta) and metformin (Glucophage,
and others) are now available as a fixed-dose combination
(Jentadueto – Boehringer Ingelheim/Lilly) for
oral treatment of type 2 diabetes in adults. Metformin
is generally the preferred first-line agent for treatment
of type 2 diabetes, but most patients eventually
require treatment with multiple drugs. Linagliptin is
a dipeptidyl peptidase-4 (DDP-4) inhibitor like
sitagliptin (Januvia) and saxagliptin (Onglyza). Both
sitagliptin and saxagliptin are also available in fixed-dose
combinations with...
Obeticholic Acid (Ocaliva) for Primary Biliary Cholangitis
The Medical Letter on Drugs and Therapeutics • Mar 27, 2017 (Issue 1517)
daily, and 54.5 with 50 mg daily vs 2.4
with placebo).
DRUG INTERACTIONS — Bile acid sequestrants can ...
Obeticholic acid (Ocaliva – Intercept), a farnesoid X
receptor agonist, has been approved by the FDA for
treatment of primary biliary cholangitis; it is indicated
for use in combination with ursodeoxycholic acid
(ursodiol, UDCA; Urso, and others) in adults with an
inadequate response to UDCA and as monotherapy in
adults unable to tolerate UDCA. Obeticholic acid is the
second drug to be approved for this indication; UDCA
was the first.
Baricitinib (Olumiant) for Rheumatoid Arthritis
The Medical Letter on Drugs and Therapeutics • Jul 16, 2018 (Issue 1551)
been reported .9
DRUG INTERACTIONS — The strong organic anion transporter
3 (OAT3) inhibitor probenecid ...
The FDA has approved the Janus kinase (JAK) inhibitor
baricitinib (Olumiant – Lilly) for oral treatment of adults
with moderately to severely active rheumatoid arthritis
(RA) that has not responded adequately to one or more
tumor necrosis factor (TNF) inhibitors. Baricitinib is
the second JAK inhibitor to be approved for treatment
of RA; tofacitinib (Xeljanz, Xeljanz XR) was the first.
PrabotulinumtoxinA (Jeuveau) for Frown Lines
The Medical Letter on Drugs and Therapeutics • May 20, 2019 (Issue 1572)
pass between treatments
80
The Medical Letter ® Vol. 61 (1572) May 20, 2019
DRUG INTERACTIONS ...
The FDA has approved prabotulinumtoxinA-xvfs
(Jeuveau – Evolus) for temporary improvement in
the appearance of moderate to severe glabellar lines
associated with corrugator and/or procerus muscle
activity. Jeuveau is the fourth botulinum toxin
product to be approved in the US for this indication
(see Table 1). It has been available in South Korea as
Nabota since 2014.
Duaklir Pressair: Another LAMA/LABA Inhaler for COPD
The Medical Letter on Drugs and Therapeutics • Sep 23, 2019 (Issue 1581)
are at increased risk.
DRUG INTERACTIONS — The hypokalemic effects of
formoterol may be potentiated ...
The FDA has approved Duaklir Pressair (Circassia), a
fixed-dose combination of the long-acting muscarinic
antagonist (LAMA) aclidinium bromide and the longacting
beta2-adrenergic agonist (LABA) formoterol
fumarate, for maintenance treatment of chronic
obstructive pulmonary disease (COPD). Aclidinium/formoterol is the fifth LAMA/LABA combination to be
approved in the US for this indication.
Long-Acting Beta-2 Agonists in Asthma
The Medical Letter on Drugs and Therapeutics • Jan 12, 2009 (Issue 1303)
EDITORIAL FELLOW: Lauren K. Schwartz, M.D., Mount Sinai School of Medicine
DRUG INTERACTIONS FELLOW ...
Continued use of a long-acting beta-2 agonist for treatment of asthma may cause down-regulation of the beta-2 receptor with loss of the bronchoprotective effect from rescue therapy with a short-acting beta-2 agonist. After a large study (SMART) found an increased risk of asthma-related deaths in patients receiving the long-acting beta-2 agonist salmeterol, a boxed warning was added to the labeling of all medications containing a long-acting beta-2 agonist. Now the FDA has completed a meta-analysis of 110 asthma treatment studies in 60,954 patients taking any of the long-acting beta-2 agonist...
Sofosbuvir (Sovaldi) for Chronic Hepatitis C
The Medical Letter on Drugs and Therapeutics • Jan 20, 2014 (Issue 1434)
is contraindicated during pregnancy
(category X).
DRUG INTERACTIONS — Sofosbuvir is a substrate of
P-glycoprotein ...
The FDA has approved the nucleotide polymerase
inhibitor sofosbuvir (Sovaldi – Gilead) for use in
combination with other antiviral drugs for treatment of
chronic hepatitis C virus (HCV) infection.
Budesonide Oral Suspension (Eohilia) for Eosinophilic Esophagitis
The Medical Letter on Drugs and Therapeutics • Jun 10, 2024 (Issue 1704)
is
expected to be negligible.9
DRUG INTERACTIONS — Budesonide is primarily
metabolized by CYP3A4. Concurrent ...
Eohilia (Takeda), an oral suspension formulation of
the corticosteroid budesonide, has been approved
by the FDA for treatment of eosinophilic esophagitis
(EoE) in patients ≥11 years old. It is the first oral
drug to be approved in the US for this indication. The
subcutaneously injected interleukin (IL)-4 receptor
antagonist dupilumab (Dupixent) is approved
for treatment of EoE in patients ≥1 year old who
weigh ≥15 kg.
Med Lett Drugs Ther. 2024 Jun 10;66(1704):93-5 doi:10.58347/tml.2024.1704c | Show Introduction Hide Introduction
Esomeprazole (Nexium)
The Medical Letter on Drugs and Therapeutics • Apr 30, 2001 (Issue 1103)
may improve absorption (Medical Letter Handbook of Adverse Drug Interactions,
2001, page 104).
DOSAGE ...
Esomeprazole magnesium (Nexium - AstraZeneca), the S-isomer of omeprazole (Prilosec), is the fifth benzimidazole proton pump inhibitor to become available in the United States. Omeprazole, which was the first, is going off patent this year.
Valdecoxib (Bextra) - a New Cyclooxygenase-2 Inhibitor
The Medical Letter on Drugs and Therapeutics • Apr 29, 2002 (Issue 1129)
).
DRUG INTERACTIONS — Concurrent use of aspirin may increase the risk of gastrointestinal ulceration ...
Valdecoxib (Bextra - Pharmacia/Pfizer), a selective cyclooxygenase (COX-2) inhibitor similar to celecoxib (Celebrex) and rofecoxib (Vioxx), was recently approved by the FDA for treatment of osteoarthritis, rheumatoid arthritis and primary dysmenorrhea.